Increased expression of GPx-1 in Bcr-Abl expressing clones exposed to imatinib might be expected to have significant impact on the clinical outcome of CML patients. This evidence concerns the gene GPX1 and chronic myelogenous leukemia, BCR-ABL1 positive.